Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma

por Smalley, Keiran SM, Fedorenko, Inna V
Publicado 2015

The complexity of microenvironment-mediated drug resistance

por Fedorenko, Inna V., Smalley, Keiran S.M.
Publicado 2015

BRAF inhibition generates a host/tumor niche that mediates therapeutic escape

por Fedorenko, Inna V., Wargo, Jennifer A., Flaherty, Keith T., Messina, Jane L., Smalley, Keiran S.M.
Publicado 2015

XL888 limits vemurafenib-induced proliferative skin events by suppressing paradoxical MAPK activation

por Phadke, Manali, Gibney, Geoffrey T., Rich, Carolyn J., Fedorenko, Inna V., Chen, Y. Ann, Kudchadkar, Ragini R., Sondak, Vernon K., Weber, Jeffrey, Messina, Jane L., Smalley, Keiran S. M.
Publicado 2015

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells

por Fedorenko, Inna V., Abel, Ethan V., Koomen, John M., Fang, Bin, Wood, Elizabeth R., Chen, Y. Ann, Fisher, Kate J., Iyengar, Sanjana, Dahlman, Kimberly B., Wargo, Jennifer A., Flaherty, Keith T., Sosman, Jeffrey A., Sondak, Vernon K., Messina, Jane L., Gibney, Geoffrey T., Smalley, Keiran S.M.
Publicado 2015